Search results
Bird Flu: What's The Latest And How Worried Should We Be?
IFLScience· 2 hours agoBird flu seems to be perennially in the news at the moment, and with more and more species...
Moderna Puts Up Big Quarterly Beat; Could Shares Break Out?
Investor's Business Daily· 6 hours agoThe Covid vaccine maker came out of the March quarter with a $3.07 loss per share, reversing from a...
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Investor's Business Daily· 7 minutes agoBut Moderna expects the lion's share of its sales to come in the second half of 2024. That lines up...
No More Yearly Flu Shots? Vaccine Mixed From 80,000 Proteins Could Be The Key
IFLScience· 2 hours agoA new vaccine strategy could spell the end of yearly flu shots, by targeting part of the virus that...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 6 hours agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Are your kids scared of needles? Health First helps remove pain, fear of getting a shot
Florida Today via Yahoo News· 1 hour agoMcGregor said. “I don’t like needles even now.” Children who develop intense anxiety around “jabs”...
Moderna revenues plummeted after sales of its COVID-19 vaccine fell 91%
Quartz· 4 hours agoModerna’s first-quarter revenue was slashed nearly in half over the course of a year as sales of its...
Respiratory viruses levels currently minimal across Illinois
WMBD - FOX 43 Peoria· 6 days agoCHICAGO (WMBD) — The Illinois Department of Public Health reported Friday that the respiratory virus level statewide is minimal as the respiratory virus season continues to wind down. Accordi…
GSK raises forecasts on strong vaccine, HIV drug sales
BioPharma Dive via Yahoo Finance· 1 day agoSales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals...
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
Digital Journal· 6 hours agoReports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 ...